Cargando…

Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer

Chemotherapy-associated steatosis is poorly understood in the context of colorectal cancer. In this study, Stage II–III colorectal cancer patients were retrospectively selected to evaluate the frequency of chemotherapy-associated steatosis and to determine whether patients on statins throughout adju...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Michelle C. M., Kachura, Jacob J., Vlachou, Paraskevi A., Dzulynsky, Raissa, Di Tomaso, Amy, Samawi, Haider, Baxter, Nancy, Brezden-Masley, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395441/
https://www.ncbi.nlm.nih.gov/pubmed/34436031
http://dx.doi.org/10.3390/curroncol28040265
_version_ 1783744173141131264
author Lee, Michelle C. M.
Kachura, Jacob J.
Vlachou, Paraskevi A.
Dzulynsky, Raissa
Di Tomaso, Amy
Samawi, Haider
Baxter, Nancy
Brezden-Masley, Christine
author_facet Lee, Michelle C. M.
Kachura, Jacob J.
Vlachou, Paraskevi A.
Dzulynsky, Raissa
Di Tomaso, Amy
Samawi, Haider
Baxter, Nancy
Brezden-Masley, Christine
author_sort Lee, Michelle C. M.
collection PubMed
description Chemotherapy-associated steatosis is poorly understood in the context of colorectal cancer. In this study, Stage II–III colorectal cancer patients were retrospectively selected to evaluate the frequency of chemotherapy-associated steatosis and to determine whether patients on statins throughout adjuvant chemotherapy develop chemotherapy-associated steatosis at a lower frequency. Baseline and incident steatosis for up to one year from chemotherapy start date was assessed based on radiology. Of 269 patients, 76 (28.3%) had steatosis at baseline. Of the remaining 193 cases, patients receiving adjuvant chemotherapy (n = 135) had 1.57 (95% confidence interval [CI], 0.89 to 2.79) times the adjusted risk of developing steatosis compared to patients not receiving chemotherapy (n = 58). Among patients who underwent chemotherapy, those using statins for pre-existing hyperlipidemia (n = 37) had 0.71 (95% CI, 0.10 to 2.75) times the risk of developing steatosis compared to patients who were not prevalent users of statins (n = 98). Chemotherapeutic treatment of Stage II–III colorectal cancer appears to be consistent with a moderately increased risk of steatosis, although larger studies are necessary to assess the significance of this observation. Prospective trials should be considered to further explore the potential for protective use of statins in this curative patient population.
format Online
Article
Text
id pubmed-8395441
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83954412021-08-28 Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer Lee, Michelle C. M. Kachura, Jacob J. Vlachou, Paraskevi A. Dzulynsky, Raissa Di Tomaso, Amy Samawi, Haider Baxter, Nancy Brezden-Masley, Christine Curr Oncol Article Chemotherapy-associated steatosis is poorly understood in the context of colorectal cancer. In this study, Stage II–III colorectal cancer patients were retrospectively selected to evaluate the frequency of chemotherapy-associated steatosis and to determine whether patients on statins throughout adjuvant chemotherapy develop chemotherapy-associated steatosis at a lower frequency. Baseline and incident steatosis for up to one year from chemotherapy start date was assessed based on radiology. Of 269 patients, 76 (28.3%) had steatosis at baseline. Of the remaining 193 cases, patients receiving adjuvant chemotherapy (n = 135) had 1.57 (95% confidence interval [CI], 0.89 to 2.79) times the adjusted risk of developing steatosis compared to patients not receiving chemotherapy (n = 58). Among patients who underwent chemotherapy, those using statins for pre-existing hyperlipidemia (n = 37) had 0.71 (95% CI, 0.10 to 2.75) times the risk of developing steatosis compared to patients who were not prevalent users of statins (n = 98). Chemotherapeutic treatment of Stage II–III colorectal cancer appears to be consistent with a moderately increased risk of steatosis, although larger studies are necessary to assess the significance of this observation. Prospective trials should be considered to further explore the potential for protective use of statins in this curative patient population. MDPI 2021-08-09 /pmc/articles/PMC8395441/ /pubmed/34436031 http://dx.doi.org/10.3390/curroncol28040265 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Michelle C. M.
Kachura, Jacob J.
Vlachou, Paraskevi A.
Dzulynsky, Raissa
Di Tomaso, Amy
Samawi, Haider
Baxter, Nancy
Brezden-Masley, Christine
Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer
title Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer
title_full Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer
title_fullStr Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer
title_full_unstemmed Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer
title_short Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer
title_sort evaluation of adjuvant chemotherapy-associated steatosis (cas) in colorectal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395441/
https://www.ncbi.nlm.nih.gov/pubmed/34436031
http://dx.doi.org/10.3390/curroncol28040265
work_keys_str_mv AT leemichellecm evaluationofadjuvantchemotherapyassociatedsteatosiscasincolorectalcancer
AT kachurajacobj evaluationofadjuvantchemotherapyassociatedsteatosiscasincolorectalcancer
AT vlachouparaskevia evaluationofadjuvantchemotherapyassociatedsteatosiscasincolorectalcancer
AT dzulynskyraissa evaluationofadjuvantchemotherapyassociatedsteatosiscasincolorectalcancer
AT ditomasoamy evaluationofadjuvantchemotherapyassociatedsteatosiscasincolorectalcancer
AT samawihaider evaluationofadjuvantchemotherapyassociatedsteatosiscasincolorectalcancer
AT baxternancy evaluationofadjuvantchemotherapyassociatedsteatosiscasincolorectalcancer
AT brezdenmasleychristine evaluationofadjuvantchemotherapyassociatedsteatosiscasincolorectalcancer